 |
 |
 |
 |
 |
 |
Faster Cures interviews SGC Director Aled Edward on their Innovators spotlight.
Aled Edwards: Carrying Out Open-Access Research in Structural and Chemical Biology
SGC Press Releases
Wednesday 7th May 2014
The Group led by Professor Chas Bountra, Chief Scientist of SGC Oxford, has been awarded the Royal Society of Chemistry's Rita and John Cornforth Award 2014 for "... world leading collaborative research across the disciplines of structural biology, medicinal chemistry, chemical biology and enzymology towards understanding and exploiting the potential of epigenetics as a target family for future drug discovery".
Tuesday 25th February 2014
The Structural Genomics Consortium (SGC) and DiscoveRx Corporation announced the publication of findings demonstrating that several clinical kinase inhibitors also potently inhibit diverse bromodomain epigenetic reader proteins. This study titled “Dual kinase-bromodomain inhibitors for rationally designed polypharmacology”, which appears on-line today in Nature Chemical Biology , suggests compelling new multi-targeting approaches for cancer therapy.
Thursday 19th December 2013
Bayer Inc. is pleased to announce that Bayer HealthCare has joined the SGC, a not-for-profit, public-private partnership with active research facilities at the Universities of Toronto and Oxford, UK.
Sunday 27th October 2013
The Structural Genomics Consortium (SGC) announced today that Janssen Pharmaceuticals NV has joined its group to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines.
Tuesday 7th May 2013
Boehringer Ingelheim announced that it has joined the Structural Genomics Consortium (SGC) for further research into incurable diseases.
Tuesday 2nd April 2013
A group led by Dr. Liz Carpenter at the Structural Genomics Consortium have now mapped all the atoms that build ZMPSTE24 using a technique called X-ray crystallography and found a completely novel fold – the way in which the atoms in the enzyme are sequentially arranged.
Wednesday 19th September 2012
The Pfizer-SGC project aims to tackle a rare, hereditary metabolic disorder called homocystinuria, which leaves patients unable to metabolise the amino acid methionine.
Thursday 19th July 2012
Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.
Friday 1st June 2012
TORONTO, June 4, 2012 – The Structural Genomics Consortium (SGC), a group of expert researchers in recombinant antibody technology from the Universities of Toronto and Chicago and an industry partner have entered into a pioneering public-private partnership to generate renewable recombinant antibodies for epigenetic targets.
Pages
